ITOVEBI DIN 02555476
Status: Marketed
Holder: HOFFMANN-LA ROCHE LIMITED
Available to quote
Health Canada record
| Active ingredient(s) | INAVOLISIB 3 MG |
|---|
| Dosage form | Tablet |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION RECOMMENDED |
|---|
| Class | Human |
|---|
| ATC | L01EM06 INAVOLISIB |
|---|
| Original market date | 10-Apr-2025 |
|---|
| Current status date | 10-Apr-2025 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing INAVOLISIB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02555484 | ITOVEBI | HOFFMANN-LA ROCHE LIMITED | Tablet | INAVOLISIB 9 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 34846 | 2025-02-14 | New Drug Submission (NDS) | |
Request a quote for ITOVEBI
How to read a Canadian DIN record